This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Apr 29, 2019 (posted viaTranslators without Borders): I finished an ENG to POR project, Children's rights, 1697 words for Translators without Borders It is gratifying to contribute to this initiative....more »
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Services
Translation, Editing/proofreading
Expertise
Specializes in:
Medical: Pharmaceuticals
Medical (general)
Medical: Health Care
Also works in:
Certificates, Diplomas, Licenses, CVs
General / Conversation / Greetings / Letters
Environment & Ecology
Business/Commerce (general)
Marketing / Market Research
More
Less
Volunteer / Pro-bono work
Open to considering volunteer work for registered non-profit organizations
English to Portuguese: Clinical protocol amendment General field: Medical Detailed field: Medical: Pharmaceuticals
Source text - English Please note the following clarification to the protocol dated 20 June 2010.
1. A modification to Exclusion criterion 209 was made to align with Exclusion criterion 211. Specifically, per Exclusion criteria 211, the chronic use of low-dose corticosteroid is permitted, however, Exclusion criteria 209 does not specify that the use of low-dose corticosteroids is permitted. As such, Exclusion Criterion 209 was modified to:
"Exclusion Criterion 209: Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs for active inflammatory disease, including small or large intestine inflammation such as Crohn’s disease or ulcerative colitis, which requires immunosuppressive therapy. Low doses of steroids (equivalent to
Translation - Portuguese Segue abaixo o esclarecimento quanto ao protocolo, datado de 20 de junho de 2010.
1. O critério de exclusão 209 foi alterado para harmonizar-se com o critério de exclusão 211. Especificamente, de acordo com o critério de exclusão 211, o uso crônico de corticosteroides em dose baixa é permitido; porém, o critério de exclusão 209 não especifica que o uso de corticosteroides em dose baixa é permitido. Dessa forma, o critério de exclusão 209 foi alterado para:
"Critério de exclusão 209: Doença autoimune ativa não controlada por anti-inflamatórios não-esteroides para doença inflamatória ativa, incluindo inflamação do intestino grosso ou delgado, como doença de Crohn ou colite ulcerativa, que requer terapia imunossupressora. Doses baixas de esteroides (equivalentes a
English to Portuguese: Article General field: Medical Detailed field: Medical: Health Care
Source text - English Gaucher disease (GD) is characterized by high treatment costs and a significant burden to patients in the form of physical and emotional impairment. Unmet need remains for new high-value treatment options offering security of supply. XXXX is an ERT product for GD which, being derived from carrot cells, is not vulnerable to mammalian viral contamination and provides the reassurance of continuity in supply.
Although GD is rare, the associated burden for patients is significant. Typical manifestations include hepatomegaly, splenomegaly, anemia, and thrombocytopenia, along with skeletal and bone complications. GD weakens the immune systems of sufferers and leads to an increased incidence of peripheral neuropathy, Parkinson’s disease, hematologic malignancies and pancreatic cancer. Physical pain (particularly bone pain) and fatigue, which have a major negative impact on physical well-being, are among the most common symptoms experienced by patients, who also report sadness, anxiety and depression. Crucially, GD patients have a shorter life expectancy than people who do not have the disease. The economic burden of GD is substantial. The annual cost of ERT can be as high as US$600,000 per patient. Besides the burden that it poses to payers, the high cost of treatment is also a burden to patients, a majority of whom report emotional stress relating to the financial aspects of treatment. Due to the treatment cost, the career choices of a significant proportion of GD patients are affected by insurance concerns and coverage.
Translation - Portuguese A doença de Gaucher (DG) é caracterizada pelos altos custos do tratamento e pela carga significativa para os pacientes na forma de comprometimento físico e emocional. Ainda há necessidades não satisfeitas quanto a novas opções de tratamento de valor elevado que ofereçam segurança de fornecimento. XXXX é um produto para terapia de reposição enzimática (TRE) para a DG que, por ser proveniente de células de cenoura, não é vulnerável à contaminação viral de mamíferos e proporciona a garantia de continuidade do fornecimento.
Embora a DG seja rara, a carga associada para os pacientes é significativa. As manifestações típicas incluem hepatomegalia, esplenomegalia, anemia e trombocitopenia, além de complicações ósseas e esqueléticas. A DG enfraquece o sistema imunológico de seus portadores e provoca o aumento da incidência de neuropatia periférica, doença de Parkinson, doenças malignas hematológicas e câncer de pâncreas. A dor física (principalmente dor óssea) e a fadiga, que causam grande impacto negativo no bem-estar físico, estão entre os sintomas mais comuns apresentados pelos pacientes, que também relatam tristeza, ansiedade e depressão. Fundamentalmente, pacientes com DG têm uma expectativa de vida mais curta do que as pessoas que não têm a doença. A carga econômica da DG é substancial. O custo anual da TRE pode chegar a US$ 600.000 por paciente. Além da carga que representa para os pagadores, o alto custo do tratamento é também uma carga para os pacientes, sendo que a maioria deles refere estresse emocional relacionado aos aspectos financeiros do tratamento. Devido ao custo do tratamento, as opções de carreira de uma proporção significativa de pacientes com DG são afetadas por questões relacionados ao seguro e à cobertura.
More
Less
Translation education
Graduate diploma - Unibero - Centro Universitário Ibero Americano
Experience
Years of experience: 15. Registered at ProZ.com: Jun 2010.
Stay up to date on what is happening in the language industry
Bio
I am a Brazilian full time translator and proofreader providing services to translation agencies since 2009. My specializations include medical and pharmaceutical translations; my work to date has involved translation and proofreading of clinical trial documents (such as protocols, brochures, ICFs, patient information, patient reports, CIOMS, clinical trial agreements, etc.), documents related to drug regulatory affairs and quality control (such as stability reports, descriptions of manufacturing processes, in process controls, methods of analysis, etc.) and market research. I also translate and review documents related to the environment.
[
